Bortezomib
t(14;16)
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the t(14;16) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Monomethyl Fumarate Fred Hutchinson Cancer Center | Phase 2 | B |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 2 | B |
Cytosin-Arabinosid Fred Hutchinson Cancer Center | Phase 2 | B |
FILGRASTIM Fred Hutchinson Cancer Center | Phase 2 | B |
CARMUSTINE Fred Hutchinson Cancer Center | Phase 2 | B |
View all 10 →
Same molecule, other indications
Bortezomib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →